PAHC
Price
$39.45
Change
+$0.38 (+0.97%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.6B
60 days until earnings call
PBH
Price
$64.98
Change
-$1.77 (-2.65%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.2B
54 days until earnings call
Interact to see
Advertisement

PAHC vs PBH

Header iconPAHC vs PBH Comparison
Open Charts PAHC vs PBHBanner chart's image
Phibro Animal Health
Price$39.45
Change+$0.38 (+0.97%)
Volume$4.9K
Capitalization1.6B
Prestige Consumer Healthcare
Price$64.98
Change-$1.77 (-2.65%)
Volume$6.03K
Capitalization3.2B
PAHC vs PBH Comparison Chart in %
Loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAHC vs. PBH commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a StrongBuy and PBH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (PAHC: $39.07 vs. PBH: $66.75)
Brand notoriety: PAHC and PBH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PAHC: 123% vs. PBH: 97%
Market capitalization -- PAHC: $1.6B vs. PBH: $3.2B
PAHC [@Pharmaceuticals: Generic] is valued at $1.6B. PBH’s [@Pharmaceuticals: Generic] market capitalization is $3.2B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 1 FA rating(s) are green whilePBH’s FA Score has 0 green FA rating(s).

  • PAHC’s FA Score: 1 green, 4 red.
  • PBH’s FA Score: 0 green, 5 red.
According to our system of comparison, PAHC is a better buy in the long-term than PBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 5 TA indicator(s) are bullish while PBH’s TA Score has 4 bullish TA indicator(s).

  • PAHC’s TA Score: 5 bullish, 4 bearish.
  • PBH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than PBH.

Price Growth

PAHC (@Pharmaceuticals: Generic) experienced а +1.92% price change this week, while PBH (@Pharmaceuticals: Generic) price change was -0.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

PAHC is expected to report earnings on Nov 05, 2025.

PBH is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBH($3.2B) has a higher market cap than PAHC($1.6B). PAHC has higher P/E ratio than PBH: PAHC (33.15) vs PBH (15.27). PAHC YTD gains are higher at: 88.523 vs. PBH (-14.522). PAHC has less debt than PBH: PAHC (762M) vs PBH (1.04B).
PAHCPBHPAHC / PBH
Capitalization1.6B3.2B50%
EBITDAN/A362M-
Gain YTD88.523-14.522-610%
P/E Ratio33.1515.27217%
RevenueN/A1.12B-
Total CashN/A140M-
Total Debt762M1.04B73%
FUNDAMENTALS RATINGS
PAHC vs PBH: Fundamental Ratings
PAHC
PBH
OUTLOOK RATING
1..100
208
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
3844
SMR RATING
1..100
6463
PRICE GROWTH RATING
1..100
3684
P/E GROWTH RATING
1..100
10068
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBH (84) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than PBH’s over the last 12 months.

PAHC's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is in the same range as PBH (44) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to PBH’s over the last 12 months.

PBH's SMR Rating (63) in the Pharmaceuticals Other industry is in the same range as PAHC (64) in the Pharmaceuticals Major industry. This means that PBH’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBH (84) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than PBH’s over the last 12 months.

PBH's P/E Growth Rating (68) in the Pharmaceuticals Other industry is in the same range as PAHC (100) in the Pharmaceuticals Major industry. This means that PBH’s stock grew similarly to PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCPBH
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
44%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 8 days ago
57%
Declines
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 26 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
57%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JMVZX33.710.29
+0.87%
JPMorgan Mid Cap Value R2
IRVAX25.630.19
+0.75%
Voya Russell Large Cap Value Idx Port A
PGEJX27.800.20
+0.72%
George Putnam Balanced R6
ECHSX12.900.05
+0.39%
Eaton Vance Worldwide Health Sci C
MGQAX17.93N/A
N/A
Morgan Stanley Inst Global Stars A

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+2.29%
AMRX - PAHC
46%
Loosely correlated
+0.10%
ZTS - PAHC
41%
Loosely correlated
+0.51%
PBH - PAHC
38%
Loosely correlated
-0.24%
ELAN - PAHC
37%
Loosely correlated
+0.69%
VTRS - PAHC
36%
Loosely correlated
-2.09%
More

PBH and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBH has been loosely correlated with PAHC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBH
1D Price
Change %
PBH100%
-0.24%
PAHC - PBH
38%
Loosely correlated
+2.29%
PRGO - PBH
30%
Poorly correlated
-0.17%
AMRX - PBH
27%
Poorly correlated
+0.10%
AMPH - PBH
27%
Poorly correlated
-0.68%
APNHF - PBH
26%
Poorly correlated
N/A
More